Dexniguldipine
Star0
Identification
- Generic Name
- Dexniguldipine
- DrugBank Accession Number
- DB14068
- Background
-
Not Available
- Type
- Small Molecule
- Groups
- Experimental
- Structure
-
- Weight
-
Average: 609.723
Monoisotopic: 609.283885988 - Chemical Formula
- C36H39N3O6
- Synonyms
-
- (+)-niguldipine
- (R)-niguldipine
- Dexniguldipine
Pharmacology
- Indication
-
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning models
with evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets. - Contraindications & Blackbox Warnings
-
Avoid life-threatening adverse drug eventsImprove clinical decision support with information oncontraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.
- Pharmacodynamics
-
Not Available
- Mechanism of action
-
Target Actions Organism UP-glycoprotein 1 inhibitorHumans - Absorption
-
Not Available
- Volume of distribution
-
Not Available
- Protein binding
-
Not Available
- Metabolism
- Not Available
- Route of elimination
-
Not Available
- Half-life
-
Not Available
- Clearance
-
Not Available
- Adverse Effects
-
提高决策支持与研究成果With structured adverse effects data, including:blackbox warnings, adverse reactions, warning & precautions, & incidence rates.提高决策支持与研究成果with our structured adverse effects data.
- Toxicity
-
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRsBrowse all" title="" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug InteractionsLearn More" title="" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
-
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbaloparatide Abaloparatide may increase the hypotensive activities of Dexniguldipine. Abametapir The serum concentration of Dexniguldipine can be increased when it is combined with Abametapir. Abemaciclib The serum concentration of Abemaciclib can be increased when it is combined with Dexniguldipine. Acarbose The risk or severity of hypoglycemia can be increased when Dexniguldipine is combined with Acarbose. Acebutolol Acebutolol may increase the arrhythmogenic activities of Dexniguldipine. Aceclofenac The therapeutic efficacy of Dexniguldipine can be decreased when used in combination with Aceclofenac. Acemetacin The therapeutic efficacy of Dexniguldipine can be decreased when used in combination with Acemetacin. Acetohexamide The risk or severity of hypoglycemia can be increased when Dexniguldipine is combined with Acetohexamide. Acetyldigitoxin Acetyldigitoxin may increase the arrhythmogenic activities of Dexniguldipine. Acetylsalicylic acid Acetylsalicylic acid may decrease the antihypertensive activities of Dexniguldipine. Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Products
-
Drug product information from 10+ global regionsOur datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions. - Product Ingredients
-
Ingredient UNII CAS InChI Key Dexniguldipine hydrochloride 0642TZ1JZN 113145-70-3 MHOSUIMBPQVOEU-MGDILKBHSA-N
Categories
- Drug Categories
-
- Agents causing hyperkalemia
- Antiarrhythmic agents
- Antihypertensive Agents
- Antineoplastic Agents
- Bradycardia-Causing Agents
- Calcium Channel Blockers
- Calcium-Regulating Hormones and Agents
- Cytochrome P-450 CYP3A Substrates
- Cytochrome P-450 CYP3A4 Substrates
- 细胞色素p - 450潜艇trates
- Membrane Transport Modulators
- P-glycoprotein inhibitors
- Pyridines
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- N9DG6ZTC43
- CAS number
- 120054-86-6
- InChI Key
- SVJMLYUFVDMUHP-MGBGTMOVSA-N
- InChI
-
InChI=1S/C36H39N3O6/c1-25-31(34(40)44-3)33(27-12-10-17-30(24-27)39(42)43)32(26(2)37-25)35(41)45-23-11-20-38-21-18-36(19-22-38,28-13-6-4-7-14-28)29-15-8-5-9-16-29/h4-10,12-17,24,33,37H,11,18-23H2,1-3H3/t33-/m1/s1
- IUPAC Name
-
3-[3-(4,4-diphenylpiperidin-1-yl)propyl] 5-methyl (4R)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
- SMILES
-
[H]N1C(C)=C([C@@H](C2=CC(=CC=C2)[N+]([O-])=O)C(C(=O)OCCCN2CCC(CC2)(C2=CC=CC=C2)C2=CC=CC=C2)=C1C)C(=O)OC
References
- General References
- Not Available
- External Links
-
- ChemSpider
- 5293311
- ChEBI
- 103932
- ChEMBL
- CHEMBL2051956
- ZINC
- ZINC000100057432
Clinical Trials
- Clinical TrialsLearn More" title="" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
-
Phase Status Purpose Conditions Count
Pharmacoeconomics
- Manufacturers
-
Not Available
- Packagers
-
Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
-
Property Value Source Water Solubility 0.000113 mg/mL ALOGPS logP 6.27 ALOGPS logP 5.6 Chemaxon logS -6.7 ALOGPS pKa (Strongest Acidic) 19.47 Chemaxon pKa (Strongest Basic) 9.59 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 7 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 111.01 Å2 Chemaxon Rotatable Bond Count 12 Chemaxon Refractivity 185.9 m3·mol-1 Chemaxon Polarizability 66.92 Å3 Chemaxon Number of Rings 5 Chemaxon Bioavailability 0 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets tounlock new
insights and accelerate drug research.
insights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
1. DetailsP-glycoprotein 1
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
-
Unknown
- Actions
-
Inhibitor
- General Function
- Xenobiotic-transporting atpase activity
- Specific Function
- Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
- Gene Name
- ABCB1
- Uniprot ID
- P08183
- Uniprot Name
- Multidrug resistance protein 1
- 分子量
- 141477.255 Da
References
- Hofmann J, Gekeler V, Ise W, Noller A, Mitterdorfer J, Hofer S, Utz I, Gotwald M, Boer R, Glossmann H, et al.: Mechanism of action of dexniguldipine-HCl (B8509-035), a new potent modulator of multidrug resistance. Biochem Pharmacol. 1995 Mar 1;49(5):603-9. doi: 10.1016/0006-2952(94)00479-6. [Article]
Enzymes
1. DetailsCytochrome P450 3A4
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
-
No
- Actions
-
Substrate
- General Function
- Vitamin d3 25-hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
- Gene Name
- CYP3A4
- Uniprot ID
- P08684
- Uniprot Name
- Cytochrome P450 3A4
- 分子量
- 57342.67 Da
References
- Uesawa Y, Takeuchi T, Mohri K: Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17. [Article]
Drug created at June 14, 2018 22:32 / Updated at February 21, 2021 18:54